Airway Abnormality Discovered in Autism

MIAMI BEACH – Less turned out to be better in a large clinical trial comparing radiation doses in patients treated with radiation and chemotherapy for stage III non–small cell lung cancer, investigators reported at the annual meeting of the American Society for Radiation Oncology. The median overall survival rate at 1 year was 81% for patients treated with standarddose (60 Gy) radiation, compared with 70.4% for those who received the high dose (74 Gy), according to preliminary findings from the radiationdose arm of the ongoing phase III Radiation Therapy Oncology Group (RTOG) 0617 trial. The respective median survival rates were 21.7 months and 20.7 months (P = .02). A planned interim analysis from the trial showed that the radiation comparison had crossed the prespecified boundary for futility, and the high-dose arm was stopped in June 2011, Dr. Jeffrey Bradley X-Ray Screening Doesn’t Prevent Lung Ca Deaths